Recombinant IFNAR2 Protein, Human (His Tag), Biotinylated Recombinant Proteins The human IFNAR2 (NP_997468.1) (Met1-Lys243) was expressed with a polyhistidine tag at the C-terminus.The expressed protein was biotinylated in vitro The recombinant human IFNAR2 consists of 228a.a and predicts a molecular weight of 26.2 kDa.
$ $99 In stock
Formulation: The recombinant human IFNAR2 consists of 228a.a and predicts a molecular weight of 26.2 kDa.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use

Recombinant IFNAR2 Protein, Human (His Tag), Biotinylated

Formulation: Recombinant IFNAR2 Protein was lyophilized from sterile PBS, pH 7.4.1

Source: HEK293 Cells

Product Name Recombinant IFNAR2 Protein, Human (His Tag), Biotinylated
Product Type Recombinant Protein
Source HEK293 Cells
Formulation Recombinant IFNAR2 Protein was lyophilized from sterile PBS, pH 7.4.1
Molecular Weight The recombinant human IFNAR2 consists of 228a.a and predicts a molecular weight of 26.2 kDa.
Endotoxin < 1.0 EU per μg protein as determined by the LAL method
Purity Greater than 95% as determined by SDS-PAGE.
Description The human IFNAR2 (NP_997468.1) (Met1-Lys243) was expressed with a polyhistidine tag at the C-terminus.The expressed protein was biotinylated in vitro
Host Species Homo sapiens (Human)
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
AA Sequence Met1-Lys243
Product Background Interferon-alpha/beta receptor beta chain (IFNAR2) is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNα therapy, IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNα therapy was observed only in good responders but not in poor responders. The encoded protein also functions as an antiviral factor. IFNAR2 may associate with IFNAR1 to form the type I interferon receptor. This protein serves as a receptor for interferons alpha and beta. IFNAR2 is also involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Following binding of IFNα2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNβ, it recycles back to the cell surface.
Memo IFN-alpha-REC Protein, Human;IFN-R Protein, Human;IFNABR Protein, Human;IFNARB Protein, Human
Terminal Ile 27
Bioactivity Please contact us for detailed information